Mullen P - Search Results

1

Antitumour activity of the novel flavonoid Oncamex in preclinical breast cancer models.

Martínez-Pérez C, Ward C, Turnbull AK, Mullen P, Cook G, Meehan J, Jarman EJ, Thomson PI, Campbell CJ, McPhail D, Harrison DJ, Langdon SP. Martínez-Pérez C, et al. Among authors: mullen p. Br J Cancer. 2016 Apr 12;114(8):905-16. doi: 10.1038/bjc.2016.6. Epub 2016 Mar 31. Br J Cancer. 2016. PMID: 27031849 Free PMC article.

2

Novel flavonoids as anti-cancer agents: mechanisms of action and promise for their potential application in breast cancer.

Martinez-Perez C, Ward C, Cook G, Mullen P, McPhail D, Harrison DJ, Langdon SP. Martinez-Perez C, et al. Among authors: mullen p. Biochem Soc Trans. 2014 Aug;42(4):1017-23. doi: 10.1042/BST20140073. Biochem Soc Trans. 2014. PMID: 25109996 Review.

3

Evaluation of carbonic anhydrase IX as a therapeutic target for inhibition of breast cancer invasion and metastasis using a series of in vitro breast cancer models.

Ward C, Meehan J, Mullen P, Supuran C, Dixon JM, Thomas JS, Winum JY, Lambin P, Dubois L, Pavathaneni NK, Jarman EJ, Renshaw L, Um IH, Kay C, Harrison DJ, Kunkler IH, Langdon SP. Ward C, et al. Among authors: mullen p. Oncotarget. 2015 Sep 22;6(28):24856-70. doi: 10.18632/oncotarget.4498. Oncotarget. 2015. PMID: 26259239 Free PMC article.

4

Association of c-Raf expression with survival and its targeting with antisense oligonucleotides in ovarian cancer.

McPhillips F, Mullen P, Monia BP, Ritchie AA, Dorr FA, Smyth JF, Langdon SP. McPhillips F, et al. Among authors: mullen p. Br J Cancer. 2001 Nov 30;85(11):1753-8. doi: 10.1054/bjoc.2001.2139. Br J Cancer. 2001. PMID: 11742498 Free PMC article.

5

Antisense oligonucleotide targeting of Raf-1: importance of raf-1 mRNA expression levels and raf-1-dependent signaling in determining growth response in ovarian cancer.

Mullen P, McPhillips F, MacLeod K, Monia B, Smyth JF, Langdon SP. Mullen P, et al. Clin Cancer Res. 2004 Mar 15;10(6):2100-8. doi: 10.1158/1078-0432.ccr-03-0154. Clin Cancer Res. 2004. PMID: 15041731

6

Comparison of strategies targeting Raf-1 mRNA in ovarian cancer.

Mullen P, McPhillips F, Monia BP, Smyth JF, Langdon SP. Mullen P, et al. Int J Cancer. 2006 Mar 15;118(6):1565-71. doi: 10.1002/ijc.21520. Int J Cancer. 2006. PMID: 16184551

7

Sensitivity to pertuzumab (2C4) in ovarian cancer models: cross-talk with estrogen receptor signaling.

Mullen P, Cameron DA, Hasmann M, Smyth JF, Langdon SP. Mullen P, et al. Mol Cancer Ther. 2007 Jan;6(1):93-100. doi: 10.1158/1535-7163.MCT-06-0401. Mol Cancer Ther. 2007. PMID: 17237269

8

Modulation of HER3 is a marker of dynamic cell signaling in ovarian cancer: implications for pertuzumab sensitivity.

Nagumo Y, Faratian D, Mullen P, Harrison DJ, Hasmann M, Langdon SP. Nagumo Y, et al. Among authors: mullen p. Mol Cancer Res. 2009 Sep;7(9):1563-71. doi: 10.1158/1541-7786.MCR-09-0101. Epub 2009 Sep 8. Mol Cancer Res. 2009. PMID: 19737968

9

Pertuzumab for the treatment of ovarian cancer.

Langdon SP, Faratian D, Nagumo Y, Mullen P, Harrison DJ. Langdon SP, et al. Among authors: mullen p. Expert Opin Biol Ther. 2010 Jul;10(7):1113-20. doi: 10.1517/14712598.2010.487062. Expert Opin Biol Ther. 2010. PMID: 20465533 Review.

10

Phosphoprotein pathway profiling of ovarian carcinoma for the identification of potential new targets for therapy.

Faratian D, Um I, Wilson DS, Mullen P, Langdon SP, Harrison DJ. Faratian D, et al. Among authors: mullen p. Eur J Cancer. 2011 Jun;47(9):1420-31. doi: 10.1016/j.ejca.2011.01.014. Epub 2011 Feb 18. Eur J Cancer. 2011. PMID: 21334202

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

743 results

Search Page

Filters